Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B)

Movement Disorders

Volumn 30, Issue 5, 2015, Pages 646-654

  Hauser, Robert A ^a   Isaacson, Stuart ^b   Lisk, Jerome P ^c   Hewitt, L Arthur ^d   Rowse, Gerry ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Parkinson's Disease and Movement Disorder Center of Boca Raton   (United States)

^c Southern California Movement Disorder Specialists Inc ^*  (United States)

^d LUNDBECK RESEARCH USA   (United States)

Author keywords

Droxidopa; Falls; Hypotension; Lightheadedness; Orthostatic; Parkinson's disease; Treatment

Indexed keywords

DROXIDOPA; ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; BACKACHE; CONFUSION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; GAIT DISORDER; HEMATURIA; HUMAN; HYPERTENSION; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; ORTHOSTATIC HYPOTENSION SYMPTOM ASSESSMENT; PARESTHESIA; PARKINSON DISEASE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN INJURY; SYMPTOM ASSESSMENT; URINARY TRACT INFECTION; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; FOLLOW UP; HYPOTENSION, ORTHOSTATIC; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DROXIDOPA; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; PARKINSON DISEASE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84926965977     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26086     Document Type: Article

References (29)

1. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med 2008;358:615-624.
2. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21:69-72.
3. Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag 2014;10:1-8.
4. Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord 2011;17:625-628.
5. Allcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:1470-1471.
6. Senard JM, Raï S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:584-589.
7. Gray P, Hildebrand K. Fall risk factors in Parkinson's disease. J Neurosci Nurs 2000;32:222-228.
8. Michalowska M, Fiszer U, Krygowska-Wajs A, Owczarek K. Falls in Parkinson's disease. Causes and impact on patients' quality of life. Funct Neurol 2005;20:163-168.
9. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
10. Koller WC, Glatt S, Vetere-Overfield B, Hassanein R. Falls and Parkinson's disease. Clin Neuropharmacol 1989;12:98-105.
11. Biaggioni I, Robertson D. Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency. Lancet 1987;2:1170-1172.
12. Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3, 4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 1999;53:2151-2157.
13. Mathias CJ, Senard JM, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001;11:235-242.
14. Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003;108:724-728.
15. Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014;83:328-335.
16. Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H. Randomized-withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension 2014 Oct 27. pii: HYPERTENSIONAHA.114.04035. [Epub ahead of print].
17. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res 2012;22:79-90.
18. Mathias CJ, Low PA, Freeman R, Hewitt LA, Kaufmann H. Integrated efficacy analysis of droxidopa in 2 double-blind, placebo-controlled, phase 3 studies in patients with neurogenic orthostatic hypotension. Poster presented at the Movement Disorder Society's 16th Annual International Congress of Parkinson's Disease and Movement Disorders (MDS), 17-21 June 2012, Dublin, Ireland. Poster 1296.
19. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis 2014;4:57-65.
20. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
21. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-357.
22. Gibson MJ, Andres RO, Isaacs B. A report of the Kellogg international working group on the prevention of falls in the elderly. The prevention of falls in later life. Danish Med Bull 1987;34(Suppl 4):1-23.
23. Shibao C, Grijalva CG, Raj SR, Biaggioni I, Griffin MR. Orthostatic hypotension-related hospitalizations in the United States. Am J Med 2007;120:975-980.
24. Esler M. An explanation of the unexpected efficacy of L-DOPS in pure autonomic failure. Clin Auton Res 2004;14:356-357.
25. Ahmed S, Mayo NE, Wood-Dauphinee S, Hanley JA, Cohen SR. Response shift influenced estimates of change in health-related quality of life poststroke. J Clin Epidemiol 2004;57:561-570.
26. Schwartz CE, Finkelstein JA. Understanding inconsistencies in patient-reported outcomes after spine treatment: response shift phenomena. Spine J 2009;9:1039-1045.
27. Canning CG, Sherrington C, Lord SR, et al. Exercise for falls prevention in Parkinson's disease: a randomized controlled trial [abstract]. Mov Disord 2013;28(Suppl S1):S158.
28. Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 2003;42:136-142.
29. U.S. Food and Drug Administration. Northera (droxidopa) capsules label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203202lbl.pdf. Accessed 26 July 2014.